Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $28.00 USD
Change Today 0.00 / 0.00%
Volume 0.0
TRUMF On Other Exchanges
As of 8:10 PM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

terumo corp (TRUMF) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/15 - $28.49
52 Week Low
10/21/14 - $22.67
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TERUMO CORP (TRUMF)

Related News

No related news articles were found.

terumo corp (TRUMF) Related Businessweek News

No Related Businessweek News Found

terumo corp (TRUMF) Details

Terumo Corporation manufactures and sells medical products and equipment worldwide. The company operates through Cardiac & Vascular, General Hospital, and Blood Management segments. Its cardiac and vascular products primarily comprise interventional devices that include access devices, such as introducer sheaths, guidewires, and guiding catheters; therapeutic devices, which include balloon catheters and stents; intravascular imaging systems; and cardiopulmonary bypass systems comprising oxygenator with integrated arterial filters, heart-lung machines, and artificial thoracic vascular grafts. The company’s general hospital products principally include infusion systems, including infusion pumps, infusion solutions, IV catheter, and infusion line connectors; drug and devices comprising prefilled syringes and prefillable syringes; nutritional supplements; measuring devices systems with communication functions, such as blood glucose meters, blood pressure monitors, and thermometers; pain management medicines that include analgesic and antiemetic; and closed anticancer drug infusion systems. Its blood management products primarily comprise automated blood collection systems, blood bag systems with leukocyte reduction filters, automated blood component processing system, pathogen reduction technology systems, therapeutic apheresis systems, and cell expansion systems. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.

19,934 Employees
Last Reported Date: 06/25/15
Founded in 1921

terumo corp (TRUMF) Top Compensated Officers

Senior Executive Officer, Director, Chief Exe...
Total Annual Compensation: ¥108.0M
Compensation as of Fiscal Year 2015.

terumo corp (TRUMF) Key Developments

Terumo Corporation Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2015; Provides Earnings Guidance for the Half Year Ending September 2015 and Full Year Ending March 2016; Provides Interim and Year-End Dividend Guidance for the Year Ending March 2016

Terumo Corporation announced consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported net sales of JPY 128,660 million compared to JPY 114,945 million, operating income of JPY 19,449 million compared to JPY 16,114 million, ordinary income of JPY 20,592 million compared to JPY 14,449 million and net income of JPY 14,504 million or JPY 35.83 per diluted share compared to JPY 8,394 million or JPY 22.10 per basic share for the last year. Income before income taxes and minority interests was JPY 20,632 million compared to JPY 13,765 million for the last year. The company provided earnings guidance for the half year ending September 2015. For the half year, the company expects net sales of JPY 250,000 million, operating income of JPY 31,000 million, ordinary income of JPY 29,500 million and profit attributable to owners of parent of JPY 17,500 million or JPY 46.09 per share. The company provided earnings guidance for the full year ending March 2016. For the year, the company expects net sales of JPY 520,000 million, operating income of JPY 70,000 million, ordinary income of JPY 67,000 million and net income of JPY 39,500 million or JPY 104.04 per share. The company provided interim dividend guidance of JPY 16 per share compared to JPY 14.50 per share a year ago. The company provided year-end dividend guidance of JPY 16 per share and total dividend of JPY 32 per share for the year ending March 31, 2016 compared to year-end dividend of JPY 16 per share and total dividend of JPY 30.50 per share a year ago.

Terumo Corporation, Q1 2016 Earnings Call, Aug 04, 2015

Terumo Corporation, Q1 2016 Earnings Call, Aug 04, 2015

Terumo Corporation to Report Q1, 2016 Results on Aug 04, 2015

Terumo Corporation announced that they will report Q1, 2016 results on Aug 04, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRUMF:US $28.00 USD 0.00

TRUMF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $190.39 USD -1.47
Edwards Lifesciences Corp $137.55 USD -1.48
Hospira Inc $89.95 USD 0.00
Olympus Corp ¥4,100 JPY -50.00
Teleflex Inc $129.17 USD +1.07
View Industry Companies

Industry Analysis


Industry Average

Valuation TRUMF Industry Range
Price/Earnings 28.7x
Price/Sales 2.4x
Price/Book 2.1x
Price/Cash Flow 27.7x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TERUMO CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at